Neurovascular Product Surveillance Registry

For MDT16056 and MDT17077

Inclusion Criteria:

• Patient or legally authorized representative (LAR) provides authorization and/orconsent per institution and geographical requirements

• Patient has, or is intended to receive or be treated with, an eligible Medtronicproduct

• Patient is consented within the enrollment window of the therapy received, asapplicable

• Patient is at least 18 years of age at time of enrollment.

Exclusion Criteria:

• Patient who is, or is expected to be inaccessible for follow-up

• Patient with exclusion criteria required by local law

• Patient is currently enrolled in or plans to enroll in any concurrent drug and/ordevice study that may confound results

• Female patient who is known to be pregnant or is breastfeeding or wishes to becomepregnant during participation in the study.

For MDT24028 and MDT22032:

General Inclusion Criteria:

• Patient or legally authorized representative (LAR) provides authorization and/orconsent per institution and geographical requirements.

• Patient is treated or intended to be treated with an eligible MedtronicNeurovascular product.

• Patient is an adult per local law at time of consent. Medtronic Business RestrictedThis document is electronically controlled CONFIDENTIAL 056-F275 Rev F ClinicalInvestigation Plan Template

General Exclusion Criteria:

• Patient who may be unable to complete the study follow-up

• Patient with any contraindications per the applicable Instructions for Use document

• Female patient who is known to be pregnant or is breastfeeding or wishes to becomepregnant during participation in the study

• Patient is currently enrolled in, or plans to enroll in, any concurrent drug/devicestudy that may confound the study results.

Additional criteria may be required, refer to cohort-specific Addendum, as applicable, for further guidance.